Perspective Therapeutics
Develops image-guided lead-212 cancer therapies with paired lead-203 imaging.
$3.21
After-hours close+0.11 (+3.67%)
At close$3.10(−2.67%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders —
Shares outstanding 114.05M · Float 68.30M · 59.9% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Commodore Capital LP | 9.90% | 11.94M | 13G | Feb 9, 2026 ↗ |
| FMR LLCincl. Abigail P. Johnson | 8.16% | 5.50M | Nov 7, 2024 ↗ | |
| Ein #incl. Janus Henderson Group plc | 7.10% | 4.80M | Nov 14, 2024 ↗ | |
| BlackRock, Inc. | 6.80% | 7.78M | 13G | Jul 29, 2026 ↗ |
| Qatar Investment Authority | 6.20% | 7.07M | 13G | Feb 5, 2026 ↗ |
| State Street Corporation | 5.30% | 6.05M | 13G | Aug 7, 2026 ↗ |
| Millennium Management LLC | 5.30% | 6.04M | 13G | Jul 20, 2026 ↗ |
| Avidity Partners Management LP | 5.30% | 6.05M | 13G | Mar 10, 2026 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.